Novel drug delivery technology will also make it possible to deliver STING agonists to certain cell populations to specifically elicit anti-immune response without activating STING where it might aid tumor progression (Wang et al., 2020; Li et al., 2021b). This evidence concerns the gene STING1 and neoplasm.